FGFR2 and cholangiocarcinoma: To date, the FDA has approved erdafitinib for urothelial cancer with FGFR2 or FGFR3 alterations, as well as pemigatinib and infigratinib for cholangiocarcinoma with FGFR2 fusions or other rearrangements.9, 10, 11